A dominant trend in the psychedelic research literature is the concentration of clinical trial activity around cancer patients—particularly those with advanced or life-threatening disease—as the flagship population for psilocybin- and LSD-assisted psychotherapy. Across the reviewed studies, cancer diagnoses account for the overwhelming majority of trial participants, reflecting a therapeutic thesis that the psychological burden of terminal or advanced illness (existential distress, demoralization, depression, anxiety, and pain) is mechanistically distinct from primary psychiatric disease and uniquely responsive to psychedelic intervention. Structured protocols such as PEARL therapy and PARTING exemplify the emerging treatment architecture: preparation sessions, a monitored high-dose psilocybin or LSD session, and integration/psychotherapeutic support sessions, all conducted in controlled clinical settings rather than recreational contexts. This "set and setting" framework, reinforced by trip-sitter/nurse supervision and management of adverse psychological reactions (bad trips), is treated as a suprapharmacological determinant of outcome as important as the drug itself.
Clinical efficacy is measured through validated instruments—Montgomery-Åsberg Depression Rating Scale, Hamilton Anxiety Rating Scale—tracked from baseline through pre-dose and post-dosing assessments, with standardized mean differences (Hedges g) used to pool effects across heterogeneous open-label trials, pilot studies, and randomized controlled trials. Feasibility assessment (recruitment, retention, adherence) is emphasized alongside efficacy, reflecting the field's transition from proof-of-concept to more rigorous trial design, while safety monitoring captures characteristic adverse events (nausea, headache, transient hypertensive episodes) and rarer risks like emergent suicidal ideation. Demoralization and existential distress are positioned as intermediary constructs linking cancer diagnosis to diminished quality of life and increased symptom burden, forming a causal chain that psilocybin-assisted psychotherapy aims to interrupt via still-undetermined psychological and biological mechanisms, plausibly connected to serotonergic (5-HT) signaling implicated in depression pathophysiology.
Beyond oncology, the same therapeutic model is being extended to comorbid and adjacent conditions—smoking cessation (including in people with HIV, where depression and anxiety act as barriers to standard cessation treatment), substance use disorders such as cocaine use disorder, PTSD, borderline personality disorder, and treatment-resistant depression—suggesting a broader trajectory toward transdiagnostic application of classical (psilocybin, LSD) and nonclassical/dissociative psychedelic agents. Collectively, this evidence base signals a maturation from small open-label pilots toward controlled, mechanism-focused trials, with cancer-related psychiatric distress serving as the paradigmatic use case driving methodological standards (feasibility metrics, statistical rigor, safety profiling) now being generalized across the psychedelic-assisted therapy field.